Search Result

Results for "

SMARCA2/4-IN-4

" in MedChemExpress (MCE) Product Catalog:

By Targets:	DNA/RNA Synthesis (1) Epigenetic Reader Domain (7) Ligands for Target Protein for PROTAC (1) Molecular Glues (1) PROTACs (9) SWI/SNF Complex (7)
By Research Areas:	Cancer (14) Inflammation/Immunology (1)
Click Chemistry:	Azide (1)

Inhibitors & Agonists

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-159607

PRT3789	PROTACs SWI/SNF Complex	Cancer
PRT3789 is a selective SMARCA2 PROTAC degrader (DC₅₀ in HeLa cell: 0.72 nM for SMARCA2, 14 nM for SMARCA4). PRT3789 forms a stable ternary complex with Von Hippel-Lindau (VHL) E3 ligase, induces polyubiquitination at SMARCA2-specific lysine residues, and drives proteasome-dependent SMARCA2 degradation. PRT3789 disrupts SWI/SNF chromatin remodeling complex integrity, induces dissociation of specific subunits, suppresses oncogenic gene expression, reduces chromatin accessibility, and upregulates antigen processing/presentation-related gene expression. PRT3789 induces synthetic lethality, inhibits proliferation and colony formation, and drives tumor growth inhibition and regression in SMARCA4-deficient contexts. PRT3789 can be used for the research of SMARCA4-mutated solid tumors, non-small cell lung cancer, endometrial cancer, colorectal cancer, bladder cancer, esophageal cancer, ovarian cancer, and gastric cancer .

HY-176871

PROTAC SMARCA2 degrader-35	PROTACs SWI/SNF Complex DNA/RNA Synthesis	Cancer
PROTAC SMARCA2 degrader-35 (Compound 43) is a selective *SMARCA2* PROTAC degrader with a DC₅₀ < 0.1 μM for SMARCA2. PROTAC SMARCA2 degrader-35 has anticancer activity and regulates cancer cell proliferation and growth through cell cycle arrest and DNA replication inhibition in SMARCA4-deleted cancer cells .

HY-153361

YD23	PROTACs Epigenetic Reader Domain	Inflammation/Immunology Cancer
YD23 is a selective SMARCA2 PROTAC degrader with DC₅₀ values of 64 nM and 297 nM in H1792 cells and H1975 cells. YD23 induces degradation of SMARCA2, which is synthetic lethal to SMARCA4. YD23 reduces chromatin accessibility only in SMARCA4 deficient cells, including cell cycle and cell growth regulatory genes. YD23 selectively inhibits growth of SMARCA4 mutant lung cancer cells. YD23 has potent tumor growth inhibitory activity in SMARCA4-mutant xenografts. YD23 can be used for the study of non-small cell lung cancer (NSCLC) .

HY-170824

SMD-3236	PROTACs SWI/SNF Complex Epigenetic Reader Domain	Cancer
SMD-3236 is a *SMARCA2* PROTAC degrader with a DC₅₀ of 0.5 nM, a D_max of 98%, and an IC₅₀ of 42.2 nM against human *SMARCA2. SMD-3236 induces proteasome- and ubiquitin-like modification-dependent degradation of SMARCA2* protein by binding to *SMARCA2* and VHL-1. SMD-3236 inhibits the growth of *SMARCA4*-deficient cancer cells. SMD-3236 induces significant and persistent depletion of *SMARCA2* in tumor tissues. SMD-3236 suppresses tumor growth in *SMARCA4*-deficient human cancer xenograft models. SMD-3236 can be used in research related to *SMARCA4*-deficient cancers such as melanoma, non-small cell lung cancer, and acute myeloid leukemia .

HY-175756

SMARCA2/4 degrader-1	Molecular Glues SWI/SNF Complex	Cancer
SMARCA2/4 degrader-1 is a *SMARCA2/4* molecular glue degrader with a DCAF16 EC₅₀ of 110 nM. SMARCA2/4 degrader-1 covalently adducts at cysteine to form a ternary complex with SMARCA2/4 and recruits CUL4 ^DCAF16 and CRL1 ^FBXO22 E3 ligase complexes. SMARCA2/4 degrader-1 induces ubiquitination and proteasomal degradation of SMARCA2/4. SMARCA2/4 degrader-1 can be used for research of SMARCA4-deficient malignancies, non-small cell lung cancer (NSCLC), and colorectal cancer .

HY-W494890

SMARCA2-IN-10	Epigenetic Reader Domain	Cancer
SMARCA2-IN-10 (Compound 4) is a highly selective SMARCA2 ATPase domain inhibitor (IC₅₀=17.676 μM). SMARCA2-IN-10 induces cell death in SMARCA4-deficient tumors. SMARCA2-IN-10 is promising for research of SMARCA4-mutant non-small cell lung cancer, small cell ovarian carcinoma, and melanoma .

HY-159455

PROTAC SMARCA2/4-degrader-4	PROTACs Epigenetic Reader Domain	Cancer
PROTAC SMARCA2/4-degrader-4 (Compound I-434) is a PROTAC degrader for catalytic subunit of the SWI/SNF complex *SMARCA2* and SMARCA4. PROTAC SMARCA2/4-degrader-4 degrades *SMARCA2* in MV411 and in A549 with DC₅₀ <100 nM, degrades SMARCA4 in MV411 with DC₅₀ <100 nM. (Pink: Ligand for target protein (HY-159472); Black: Linker (HY-159478); Blue: Ligand for E3 ligase (S,R,S)-AHPC (HY-125845))

HY-162835

PROTAC SMARCA2/4-degrader-28	PROTACs Epigenetic Reader Domain	Cancer
PROTAC SMARCA2/4-degrader-28 (PROTAC 1) is a PROTAC-based partial degrader of *SMARCA2* and *SMARCA4*(Bliue: CRL2 ^VHL ligand (S,R,S)-AHPC (HY-125845); Black: linker (HY-159680); Pink: a SMARCA-BD ligand (+)-JQ-1 (HY-13030)) .

HY-161885

*SMARCA2/4-IN-4*	SWI/SNF Complex	Cancer
SMARCA2-IN-6 is a SMARCA2 and SMARCA4 inhibitor, with an IC₅₀ value of <0.005 μM for both SMARCA2 and SMARCA4. SMARCA2-IN-6 exerts anticancer activity against BRG1-mutant melanoma. SMARCA2-IN-6 can be used for research related to Brg1/Smarca4-mutant cancers .

HY-170354

**SMARCA2/4-ligand-4**	Ligands for Target Protein for PROTAC	Cancer
SMARCA2/4-ligand-4 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). SMARCA2/4-ligand-4 can be used for the synthesis of PROTAC SMARCA2/4 degrader-36 (HY-170347) .

HY-162813

PROTAC SMARCA2/4-degrader-25	PROTACs Epigenetic Reader Domain	Cancer
PROTAC SMARCA2/4-degrader-25 (compound 7d) is a PROTAC targeting *SMARCA2/4. PROTAC SMARCA2/4*-degrader-25 is composed of E3 ligase (2S,4R)-4-Hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (HY-W998248) (blue part), PROTAC Linker (S)-2-Amino-3,3-dimethylbutanoic acid (HY-59140) (black part), and target protein ligand SMARCA2/4-ligand-3 (HY-162814) (red part). The conjugate of E3 ubiquitin ligase ligand + Linker is (S,R,S)-AHPC (HY-125845) ^{[1] ^.}

HY-162815

PROTAC SMARCA2/4-degrader-26	PROTACs Epigenetic Reader Domain	Cancer
PROTAC SMARCA2/4-degrader-26 (compound 6) is a PROTAC targeting SMARCA2/4. SMARCA2 and SMARCA4 are genes and cancer targets with complementary functions that catalyze nucleosome movement. PROTAC SMARCA2/4-degrader-25 is composed of PROTAC target protein ligand 2-(4-(3-Amino-6-(2-hydroxyphenyl)pyridazin-4-yl)piperazin-1-yl)acetic acid (HY-46618) (red part), E3 ligase ligand (2S,4R)-4-Hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (HY-W998248) (blue part), PROTAC linker (S)-2-Amino-3,3-dimethylbutanoic acid (HY-59140) (black part), and the conjugate composed of E3 ubiquitin ligase ligand + Linker is (S,R,S)-AHPC (HY-125845) ^{[1] ^.}

HY-181909

PROTAC SMARCA2 degrader-36	PROTACs SWI/SNF Complex	Cancer
PROTAC SMARCA2 degrader-36 (Compound 26) is a selective and potent *SMARCA2* PROTAC degrader with a DC₅₀ of 51 nM. PROTAC SMARCA2 degrader-36 promotes ubiquitination and degradation of SMARCA2. PROTAC SMARCA2 degrader-36 exhibits anticancer activity against non-small cell lung cancer. PROTAC SMARCA2 degrader-36 can be used in studies related to *SMARCA4*-deficient cancers .

HY-185075

FHD-909 LY4050784	SWI/SNF Complex	Cancer
FHD-909 (LY4050784) is an orally active and selective SMARCA2 (BRM) ATPase inhibitor. FHD-909 potently inhibits purified BRM ATPase with an IC₅₀ of 0.0025 μM and exhibits 35.69-fold selectivity for BRM over purified SMARCA4 (BRG1) ATPase. FHD-909 induces synthetic lethality, suppresses cell proliferation, modulates target gene expression, and achieves remarkable tumor growth inhibition and regression in SMARCA4-mutant cancer cells and xenograft models. FHD-909 can be used for the research of SMARCA4/BRG1-mutant cancers, advanced solid tumors, and BAF complex-related disorders .

Cat. No.	Product Name		Classification

HY-159455

PROTAC SMARCA2/4-degrader-4		Azide
PROTAC SMARCA2/4-degrader-4 (Compound I-434) is a PROTAC degrader for catalytic subunit of the SWI/SNF complex *SMARCA2* and SMARCA4. PROTAC SMARCA2/4-degrader-4 degrades *SMARCA2* in MV411 and in A549 with DC₅₀ <100 nM, degrades SMARCA4 in MV411 with DC₅₀ <100 nM. (Pink: Ligand for target protein (HY-159472); Black: Linker (HY-159478); Blue: Ligand for E3 ligase (S,R,S)-AHPC (HY-125845))

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.